AAADV not only impacts the rate at which oncology drugs are brought to market, but patients afflicted with cancer have been able to appreciate significant advances in their care and survival rates.
Director, Office of Hematology and Oncology Drug Products
U.S. Food and Drug Administration Center for Drug Evaluation and Research
Greg Simon, executive director of the cancer moonshot task force, addressed the FDA-sponsored workshop for Accelerating Anticancer Agent Development and Validation in North Bethesda, Md., May 4.
He discussed the goals for the moonshot initiative, how the program could fit into the next presidential administration, and how to take the project international.
Simon was a former aide to Vice President Al Gore, and later helped start FasterCures, a center at the Milken Institute. In 2009, he left to become senior vice president for patient engagement at Pfizer. Since 2012, he has been working as CEO of Poliwogg, a financial services company focused on life sciences. He was named executive director of the moonshot’s task force in March.
Leaders in clinical and translational cancer research from academia, industry, government and the nonprofit advocacy sector focus on understanding and efficiently negotiating the drug development process.
May 4-6, 2017